By Prof. Shirley D’sa,
University College London Hospitals, NHS Foundation Trust
Emerging therapies show promise for treating pleural effusion, a complication of WM, according to Professor Shirley D’Sa, Professor of Haematology at University College
London Hospitals (UCLH) NHS Foundation Trust in London. Read the full article that was featured in the January 2025 Torch.
About
Prof. Shirley D’sa
Shirley D’Sa is a Professor of Haematology at University College London Hospitals (UCLH) NHS Foundation Trust in London, United Kingdom. She leads the UCLH Centre for Waldenström’s Macroglobulinaemia (WM) and Associated Disorders and serves as the haematological lead in the Joint Neurohaematology service at the National Hospital for Neurology, Queen Square, London, where she does clinics with Prof. Michael Lunn, a specialist in inflammatory neuropathies.
In addition to her clinical work, Prof. D’Sa is actively involved in clinical research, including real world data analyses, and has served as the UK Chief Investigator on several clinical trials related to WM and cold agglutinin disease, including Phase 1, 2, and 3 trials of novel therapies. She is also an enthusiastic mentor to up-and-coming haematology and neurology trainees.
Her dedication to patient care and research has established her as a leading expert in her field, with a reputation for combining clinical excellence with compassionate patient care.